The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word

Joshua Richter, MD, a multiple myeloma specialist at Mount Sinai, co–first author on the LINKER-MM1 trial—which supported the FDA approval of linvoseltamab-gcpt (Lynozyfic)—joined Gina Mauro, executive director of Oncology at MJH Life Sciences, for a conversation on where myeloma treatment stands, and where it may be headed.

The discussion covered:

• The word myeloma researchers are starting to say out loud—cure—and whether Richter believes it
• What it felt like to watch linvoseltamab move from trial data to FDA approval
• Trispecific antibodies, which target 3 sites at once, and what they could mean for patients today
• Training at St. Vincent's in the Village, one of the field's formative myeloma programs before it closed, and the lessons that era left behind
• How Richter approaches telling a patient that a drug has shown a 100% response rate in early data

The conversation closed with a round of "Myeloma or Myth," putting 5 things patients commonly believe about the disease to the test—real, false, or somewhere in between.

The Moonlight Shift is available on YouTube and across MJH Life Sciences’ oncology platforms. New episodes, released biweekly, feature leading and early-career oncologists from the tristate area in peer-level conversations about where the field is going—and what it still has to work out.